Infant Bacterial Therapeutics AB (publ)

Infant Bacterial Therapeutics AB (publ) is a biopharmaceutical company in the clinical development phase, specializing in creating treatments for serious and uncommon conditions that impact prematurely born infants. Based in Stockholm, Sweden, and established in 2013, the company's primary therapeutic candidate is IBP-9414, which aims to both prevent necrotizing enterocolitis (NEC) – a severe intestinal disease – and enhance digestive tolerance in these vulnerable newborns. Additionally, they are progressing IBP-1016, designed to address gastroschisis, a critical congenital defect affecting infants.

Infant Bacterial Therapeutics AB (publ) trades as IBT-B.ST on STO. The company is classified in Healthcare / Biotechnology and reports in SEK.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Infant Bacterial Therapeutics AB (publ) can be compared against peers such as ADDvise Group AB (publ), Cantargia AB (publ), Corline Biomedical AB, Guard Therapeutics International AB (publ), I-Tech AB, Oncopeptides AB (publ).

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $779.79M, beta of -0.46, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

IBT-B.ST currently shows total debt of N/A and beta of -0.46. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.ibtherapeutics.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.